The First On-Demand GLP-1 Maintenance Platform

Short-acting, patient-controlled appetite management for life after weight loss.

The Problem

Discontinuation Leads to Rapid Weight Regain

Clinical data shows that patients who discontinue chronic GLP-1 injectables experience rapid weight regain, with up to 68% of lost weight returning within 12 months.

The obesity market has optimized for maximal weight loss but has almost entirely ignored the maintenance phase—leaving millions of patients without a solution.

68%
Weight regain within 12 months after GLP-1 cessation
<50%
Real-world persistence on chronic GLP-1 therapies at 12 months
Our Solution

On-Demand, Short-Acting Maintenance Therapy

Metabexa is developing the first on-demand GLP-1 maintenance platform: a short-acting (4-6 hour), oral mucosal therapy designed for situational appetite control—not weight loss.

On-Demand Dosing

Patient-controlled dosing 15-60 minutes before a planned skipped meal. No daily injections, no chronic commitment.

Short-Acting Profile

Rapid onset (Tmax < 90 min) and rapid offset (4-6 hours). Matches the "hunger spike" timeframe that chronic therapies cannot address.

Oral Mucosal Delivery

Buccal or sublingual delivery bypasses first-pass metabolism, ensuring rapid absorption and patient convenience.

Oral mucosal delivery mechanism
Scientific Rationale

Using a Known GLP-1 Peptide with Proven Delivery

We are not inventing a new GLP-1 receptor agonist. We are using a known, de-risked peptide with proven short-acting precedents (e.g., Exenatide, Lixisenatide).

The innovation is in the delivery: oral mucosal administration enables rapid onset and offset, creating a pharmacokinetic profile optimized for on-demand use.

This approach de-risks the asset by focusing on formulation and delivery—not molecular discovery.

Category Creation

Maintenance is a Distinct Therapeutic Category

Weight loss requires metabolic shock. Maintenance requires behavioral control. These are fundamentally different problems requiring different pharmacology.

Weight Loss (Chronic GLP-1s)
  • •Goal: Maximal weight reduction
  • •Dosing: Daily or weekly injections
  • •Duration: Long-acting (days to weeks)
  • •Patient control: Low (fixed schedule)
Maintenance (Metabexa)
  • •Goal: Prevent weight regain
  • •Dosing: On-demand, situational
  • •Duration: Short-acting (4-6 hours)
  • •Patient control: High (self-directed)
Get in Touch

Partner with Us

We are seeking strategic partners, investors, and collaborators to advance the first on-demand GLP-1 maintenance platform.